Novavax's NanoFlu Influenza Vaccine Phase 3 Trial Meets All Primary Endpoints

BEIJING (dpa-AFX) - Novavax Inc. (NVAX) said that a complete results from a pivotal phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix-M

Related Keywords

Beijing ,China ,Stanley Erck ,Novavax Inc ,Lancet Infectious ,Chief Executive Officer ,Fluzone Quadrivalent ,பெய்ஜிங் ,சீனா ,ஸ்டான்லி ஏற்க்க் ,தலைமை நிர்வாகி அதிகாரி ,Novavax ,Nanoflu ,Influenza ,Vaccine ,Hase ,Trial ,Meets ,Primary ,Endpoints ,